单核细胞计数作为特发性肺纤维化预后生物标志物
本研究汇总四项III期随机安慰剂对照试验(ASCEND、CAPACITY、INSPIRE)的2067例IPF患者数据,回顾性分析单核细胞计数与1年内IPF进展、全因住院及全因死亡的关系。结果显示,单核细胞计数≥0.60×10^9/L较<0.60×10^9/L的患者IPF进展、住院和死亡风险均显著升高,提示单核细胞计数可作为简单廉价的预后标志物。
要点
- 单核细胞计数≥0.60×10^9/L与IPF进展、住院和死亡风险增加相关。
- 单核细胞计数从基线的变化与1年内结局无关。
- 单核细胞计数或可作为IPF简单廉价的预后生物标志物。
核心结论
- 在IPF患者中,单核细胞计数升高与IPF进展、住院和死亡风险增加相关。
- 单核细胞计数可能提供一种简单且廉价的IPF预后生物标志物。
研究设计与样本
- 回顾性汇总分析,纳入四项III期随机安慰剂对照试验(ASCEND、CAPACITY、INSPIRE)的活动组和安慰剂组患者,共2067例。
- 按基线单核细胞计数分层:<0.60×10^9 cells/L(n=1,609)、0.60至<0.95×10^9 cells/L(n=408)、≥0.95×10^9 cells/L(n=50)。
- 采用双变量和多变量模型评估单核细胞计数(定义为时间依赖性)与1年内结局的关系。
主要发现
- 调整分析中,单核细胞计数0.60至<0.95×10^9 cells/L组较<0.60×10^9 cells/L组IPF进展风险更高(P=0.016)。
- 单核细胞计数≥0.95×10^9 cells/L组较<0.60×10^9 cells/L组IPF进展风险更高(P=0.002)。
- 单核细胞计数0.60至<0.95×10^9 cells/L组和≥0.95×10^9 cells/L组较<0.60×10^9 cells/L组全因住院风险更高(P=0.030和P=0.003)。
- 单核细胞计数0.60至<0.95×10^9 cells/L组和≥0.95×10^9 cells/L组较<0.60×10^9 cells/L组全因死亡风险更高(P=0.005和P<0.001)。
- 单核细胞计数从基线的变化与1年内任何结局无关,且似乎不受研究治疗影响。
关键数值与推荐
- IPF进展定义:FVC%预计值绝对下降≥10%,或6分钟步行距离下降≥50米,或死亡。
- 单核细胞计数分层阈值:<0.60×10^9 cells/L、0.60至<0.95×10^9 cells/L、≥0.95×10^9 cells/L。
临床怎么用
- 临床可考虑将单核细胞计数作为IPF患者简单、廉价的预后评估工具。
- 单核细胞计数≥0.60×10^9 cells/L提示IPF进展、住院和死亡风险增加,需加强监测。
局限性
- 回顾性汇总分析,存在研究间异质性可能。
- 单核细胞计数≥0.95×10^9 cells/L组样本量较小(n=50)。
- 单核细胞计数从基线的变化与结局无关,其动态监测价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. Objectives: We used pooled data from pirfenidone and IFNγ-1b trials to explore the association between monocyte count and prognosis in patients with IPF. Methods: This retrospective pooled analysis included patients (active and placebo arms) from the following four phase III, randomized, placebo-controlled trials: ASCEND (NCT01366209), CAPACITY (NCT00287729 and NCT00287716), and INSPIRE (NCT00075998). Outcomes included IPF progression (≥10% absolute decline in FVC% predicted, ≥50 m decline in 6-minute-walk distance, or death), all-cause hospitalization, and all-cause mortality over 1 year. The relationship between monocyte count (defined as time-dependent) and outcomes was assessed using bivariate and multivariable models. Measurements and Main Results: This analysis included 2,067 patients stratified by monocyte count (at baseline: <0.60 × 109 cells/L [n = 1,609], 0.60 to <0.95 × 109 cells/L [n = 408], and ≥0.95 × 109 cells/L [n = 50]). In adjusted analyses, a higher proportion of patients with monocyte counts of 0.60 to <0.95 × 109 cells/L or ≥0.95 × 109 cells/L versus <0.60 × 109 cells/L experienced IPF progression (P = 0.016 and P = 0.002, respectively), all-cause hospitalization (P = 0.030 and P = 0.003, respectively), and all-cause mortality (P = 0.005 and P < 0.001, respectively) over 1 year. Change in monocyte count from baseline was not associated with any of the outcomes over 1 year and did not appear to be affected by study treatment. Conclusions: In patients with IPF, elevated monocyte count was associated with increased risks of IPF progression, hospitalization, and mortality. Monocyte count may provide a simple and inexpensive prognostic biomarker in IPF.
引用
- Kreuter M, Lee JS, Tzouvelekis A, et al. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021. PMID: 33434107. doi:10.1164/rccm.202003-0669OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。